<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01850056</url>
  </required_header>
  <id_info>
    <org_study_id>acotec-02</org_study_id>
    <nct_id>NCT01850056</nct_id>
  </id_info>
  <brief_title>AcoArt â…  / SFA China</brief_title>
  <official_title>Prospective, Multi-center and Randomized Controlled Clinical Study to Verify Effectiveness and Safety of Drug-eluting Balloon in PTA Procedure (AcoArt I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acotec Scientific Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acotec Scientific Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether DEB is more effective than common PTA&#xD;
      balloon in long-term vessel patency and inhibiting restenosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late Lumen Loss</measure>
    <time_frame>6 months</time_frame>
    <description>measure difference of the MLD(minimal lumen diameter) at 0 time and 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimal lumen diameter (MLD)</measure>
    <time_frame>6 months</time_frame>
    <description>measure minimal lumen diameter (MLD) of target lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restenosis rate of target vessel</measure>
    <time_frame>6 months, 12 months, 18 months, 24months</time_frame>
    <description>stenosis over 50% is defined as restenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target lesion revascularization</measure>
    <time_frame>6 months, 12 months, 18 months, 24 months</time_frame>
    <description>target lesion revascularization is defined as any reintervention of artery bypass graft surgery involving the target lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in Rutherford stage</measure>
    <time_frame>6 months, 12 months, 18 months, 24 months</time_frame>
    <description>based the following definition of Rutherford stage, evaluate the stage of patient. Then compare the stage of patient just after procedure and 6 months after treatment&#xD;
Stage clinical symptom&#xD;
0 asymptomatic&#xD;
mild claudication&#xD;
moderate claudication&#xD;
severe claudication&#xD;
ischemic rest pain&#xD;
minor tissue loss&#xD;
ulceration or gangrene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in ankle brachial index(ABI)</measure>
    <time_frame>6 months</time_frame>
    <description>change in ankle brachial index(ABI) compared to pretreatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major amputation</measure>
    <time_frame>6 months, 12 months, 18 months, 24 months</time_frame>
    <description>major amputation at the index limb(major amputation is defined as an amputation above the foot)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>12 months, 18 months, 24 months</time_frame>
    <description>death of any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>drug eluting balloon catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use drug eluting balloon catheter to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>common balloon catheter(uncoated drug)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>use common balloon catheter to inflate stenosis or occlusion in SFA and/or popliteal artery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug eluting balloon catheter (trade name: Orchid)</intervention_name>
    <arm_group_label>drug eluting balloon catheter</arm_group_label>
    <other_name>drug eluting dilation catheter</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>common percutaneous transluminal angioplasty balloon catheter (trade name: Admiral)</intervention_name>
    <arm_group_label>common balloon catheter(uncoated drug)</arm_group_label>
    <other_name>common PTA catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 80 years&#xD;
&#xD;
          -  Patients with peripheral artery disease (PAD), with Rutherford classification between&#xD;
             2 and 5&#xD;
&#xD;
          -  an occlusion or a minimum grade of stenosisPrimary over 70% in the superficial femoral&#xD;
             artery an /or the popliteal artery&#xD;
&#xD;
          -  Total length of treat lesion(s)is less or equal to 40cm&#xD;
&#xD;
          -  signed Patient informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  plasma Cr level greater than 150 umol/L in patients&#xD;
&#xD;
          -  patients with acute thrombosis requiring lysis or thrombectomy&#xD;
&#xD;
          -  patient with a lysis or an lower limb intervention as a therapy within the last 6&#xD;
             weeks&#xD;
&#xD;
          -  patient requiring intervention in both lower limbs at the same time&#xD;
&#xD;
          -  target lesion can't be cross by the guide wire&#xD;
&#xD;
          -  distal outflow through less than one lower leg vessel&#xD;
&#xD;
          -  known hypersensitivity to aspirin, heparin, clopidogrel,paclitaxel, contrast medium,&#xD;
             etc.&#xD;
&#xD;
          -  patients participating in another clinical trials with interfere with this trial in&#xD;
             the past 3 months&#xD;
&#xD;
          -  pregnancy and lactating woman&#xD;
&#xD;
          -  untreatable bleeding diatheses&#xD;
&#xD;
          -  other diseases, such as cancer, liver disease, or cardiac insufficiency, which may&#xD;
             lead to protocol violations or markedly shorten a patients's life expectancy(less than&#xD;
             2 years)&#xD;
&#xD;
          -  patients unable or unwilling to participate this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Xiyuan Hospital CACMS</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100091</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The second Hospital Of Hebei University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Liaoning Province</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital ShangHai Jiaotong University School Of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>April 27, 2013</study_first_submitted>
  <study_first_submitted_qc>May 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <last_update_submitted>July 11, 2018</last_update_submitted>
  <last_update_submitted_qc>July 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug eluting balloon catheter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

